Sam Brusco, Associate Editor03.27.23
Vaporox has earned U.S. Food and Drug Administration (FDA) clearance for its next-gen VHT-200 system to heal chronic wounds. The Vaporous Hyperoxia Therapy (VHT) breakthrough tech has been clinically validated as safe and effective to heal skin wounds.
VHT-200, according to the company, delivers healing rates exceeding 80% for chronic wounds. Its combination of ultrasonic mist and concentrated oxygen have been shown to accelerate healing. The company’s patented, FDA-cleared delivery system for these elements promotes revascularization and tissue growth.
The company’s Medical Director, Dr. Dustin Kruse, is a double-board-certified podiatrist in private practice. As Primary Investigator for Vaporox’s second and third clinical studies, Dr. Kruse told the press, “Overseeing the clinical study was eye opening. We consistently observed incredible healing in 20 weeks or less, even on the most complex patients, with the only variable being the addition of VHT.”
Ken Reali, the CEO of Bioventus, the company’s largest corporate investor, said, “We’re excited to see Vaporox’s technology become available to the mass market. It has the potential to transform wound healing.”
Louis Woodhill, the Chairman of Vaporox’s Board of Directors, said, “It has been profoundly satisfying to have played a role in bringing this lifesaving and life-changing technology to market. The VHT-200 represents a major step forward toward a world where all wounds heal.”
Vaporox plans to immediately begin placing VHT-200 devices with podiatrists and MDs in private practices in the U.S.
VHT-200, according to the company, delivers healing rates exceeding 80% for chronic wounds. Its combination of ultrasonic mist and concentrated oxygen have been shown to accelerate healing. The company’s patented, FDA-cleared delivery system for these elements promotes revascularization and tissue growth.
The company’s Medical Director, Dr. Dustin Kruse, is a double-board-certified podiatrist in private practice. As Primary Investigator for Vaporox’s second and third clinical studies, Dr. Kruse told the press, “Overseeing the clinical study was eye opening. We consistently observed incredible healing in 20 weeks or less, even on the most complex patients, with the only variable being the addition of VHT.”
Ken Reali, the CEO of Bioventus, the company’s largest corporate investor, said, “We’re excited to see Vaporox’s technology become available to the mass market. It has the potential to transform wound healing.”
Louis Woodhill, the Chairman of Vaporox’s Board of Directors, said, “It has been profoundly satisfying to have played a role in bringing this lifesaving and life-changing technology to market. The VHT-200 represents a major step forward toward a world where all wounds heal.”
Vaporox plans to immediately begin placing VHT-200 devices with podiatrists and MDs in private practices in the U.S.
